|
CH445129A
(fr)
|
1964-04-29 |
1967-10-15 |
Nestle Sa |
Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
|
|
US3459731A
(en)
|
1966-12-16 |
1969-08-05 |
Corn Products Co |
Cyclodextrin polyethers and their production
|
|
US3453257A
(en)
|
1967-02-13 |
1969-07-01 |
Corn Products Co |
Cyclodextrin with cationic properties
|
|
US3426011A
(en)
|
1967-02-13 |
1969-02-04 |
Corn Products Co |
Cyclodextrins with anionic properties
|
|
US3453259A
(en)
|
1967-03-22 |
1969-07-01 |
Corn Products Co |
Cyclodextrin polyol ethers and their oxidation products
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
EP0215942B1
(en)
|
1985-03-15 |
1995-07-12 |
Antivirals Inc. |
Polynucleotide assay reagent and method
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
US5087617A
(en)
|
1989-02-15 |
1992-02-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
|
US5652122A
(en)
|
1989-12-21 |
1997-07-29 |
Frankel; Alan |
Nucleic acids encoding and methods of making tat-derived transport polypeptides
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
GB9209032D0
(en)
|
1992-04-25 |
1992-06-10 |
Ciba Geigy Ag |
New peptide derivatives
|
|
EP0786522A2
(en)
|
1992-07-17 |
1997-07-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecules for treatment of stenotic conditions
|
|
NZ255831A
(en)
|
1992-08-21 |
1997-04-24 |
Biogen Inc |
Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use
|
|
CA2153158A1
(en)
|
1993-01-07 |
1994-07-21 |
Andrew Zalewski |
Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
|
|
DE69435005T2
(de)
|
1993-05-11 |
2008-04-17 |
The University Of North Carolina At Chapel Hill |
Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
|
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
IL115849A0
(en)
|
1994-11-03 |
1996-01-31 |
Merz & Co Gmbh & Co |
Tangential filtration preparation of liposomal drugs and liposome product thereof
|
|
US5849727A
(en)
|
1996-06-28 |
1998-12-15 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for altering the biodistribution of biological agents
|
|
JP2002502376A
(ja)
|
1997-05-21 |
2002-01-22 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
生物学的膜を横切る輸送を増強するための組成物および方法
|
|
US6329501B1
(en)
|
1997-05-29 |
2001-12-11 |
Auburn University |
Methods and compositions for targeting compounds to muscle
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
WO1999042091A2
(en)
|
1998-02-19 |
1999-08-26 |
Massachusetts Institute Of Technology |
Use of polycations as endosomolytic agents
|
|
US6683173B2
(en)
|
1998-04-03 |
2004-01-27 |
Epoch Biosciences, Inc. |
Tm leveling methods
|
|
EP1109821A4
(en)
|
1998-08-25 |
2002-04-03 |
Human Genome Sciences Inc |
49 HUMAN-SECRETED PROTEINS
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
JP2000125448A
(ja)
|
1998-10-14 |
2000-04-28 |
Yazaki Corp |
電気接続箱
|
|
AU778057B2
(en)
|
1999-01-29 |
2004-11-11 |
Avi Biopharma, Inc. |
Non-invasive method for detecting target RNA
|
|
JP2000256547A
(ja)
|
1999-03-10 |
2000-09-19 |
Sumitomo Dow Ltd |
耐熱性プラスチックカード用樹脂組成物
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
CA2365984A1
(en)
|
1999-04-08 |
2000-10-19 |
Oasis Biosciences, Inc. |
Antisense oligonucleotides comprising universal and/or degenerate bases
|
|
PT1178999E
(pt)
|
1999-05-04 |
2007-06-26 |
Santaris Pharma As |
Análogos de l-ribo-lna
|
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
|
EP1185637B1
(en)
|
1999-05-24 |
2008-07-23 |
Avi Biopharma, Inc. |
Antisense to c-myc for treatment of polycystic kidney disease
|
|
US6303573B1
(en)
|
1999-06-07 |
2001-10-16 |
The Burnham Institute |
Heart homing peptides and methods of using same
|
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
EP1210121A2
(en)
|
1999-08-24 |
2002-06-05 |
Cellgate Inc. |
Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
|
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
|
US20030104622A1
(en)
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
|
US7070807B2
(en)
|
1999-12-29 |
2006-07-04 |
Mixson A James |
Branched histidine copolymers and methods for using same
|
|
WO2001047496A1
(en)
|
1999-12-29 |
2001-07-05 |
Mixson A James |
Histidine copolymer and methods for using same
|
|
US20020009491A1
(en)
|
2000-02-14 |
2002-01-24 |
Rothbard Jonathan B. |
Compositions and methods for enhancing drug delivery across biological membranes and tissues
|
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
|
US20040170955A1
(en)
|
2000-09-08 |
2004-09-02 |
Wadih Arap |
Human and mouse targeting peptides identified by phage display
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
AU2002225714A1
(en)
|
2000-11-10 |
2002-05-21 |
The Regents Of The University Of California |
Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
|
|
WO2002063280A1
(en)
|
2001-02-06 |
2002-08-15 |
Auburn University |
Ligand sensor devices and uses thereof
|
|
US20030031655A1
(en)
|
2001-02-08 |
2003-02-13 |
Sequitur, Inc. |
Methods of light activated release of ligands from endosomes
|
|
JP2005508832A
(ja)
|
2001-02-16 |
2005-04-07 |
セルゲイト， インコーポレイテッド |
間隔を開けてアルギニン部分を含むトランスポーター
|
|
US7456146B2
(en)
|
2001-05-09 |
2008-11-25 |
Ghc Research Development Corporation |
Lytic peptide prodrugs
|
|
KR20040004629A
(ko)
|
2001-05-17 |
2004-01-13 |
에이브이아이 바이오파마 인코포레이티드 |
ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법
|
|
JP3735292B2
(ja)
|
2001-07-26 |
2006-01-18 |
三菱重工業株式会社 |
ダイエット効果のある健康食品および製剤
|
|
US6645974B2
(en)
|
2001-07-31 |
2003-11-11 |
Merck & Co., Inc. |
Androgen receptor modulators and methods for use thereof
|
|
US20090075377A1
(en)
|
2001-08-03 |
2009-03-19 |
Arbor Vita Corporation |
Molecular interactions in cells
|
|
JP2005514005A
(ja)
|
2001-09-04 |
2005-05-19 |
エクシコン エ／エス |
新規のｌｎａ組成物およびその使用
|
|
JP2005538035A
(ja)
|
2001-12-11 |
2005-12-15 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
グアニジニウム輸送試薬および結合体
|
|
KR100464261B1
(ko)
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
KR20030084444A
(ko)
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
CA2504554A1
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
2'-substituted oligomeric compounds and compositions for use in gene modulations
|
|
CA2796924C
(en)
|
2002-11-25 |
2016-12-13 |
Nonprofit Organization Translational Research Organization Of Duchenne Muscular Dystrophy |
Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
|
|
WO2004084805A2
(en)
|
2003-03-19 |
2004-10-07 |
The J. David Gladstone Institutes |
Acetylated tat polypeptides and methods of use thereof
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
AU2004235396B2
(en)
|
2003-04-29 |
2010-11-25 |
Sarepta Therapeutics, Inc. |
Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
|
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
US20050222068A1
(en)
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
US20050203041A1
(en)
|
2003-09-23 |
2005-09-15 |
Mourich Dan V. |
Antisense compound and method for selectively killing activated T cells
|
|
US7786151B2
(en)
|
2004-01-09 |
2010-08-31 |
Kinopharma, Inc. |
Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction
|
|
WO2005072527A2
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20060078542A1
(en)
|
2004-02-10 |
2006-04-13 |
Mah Cathryn S |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
WO2005117928A1
(en)
|
2004-05-30 |
2005-12-15 |
Cemines, Inc. |
Compositions and methods for the treatment of skin cancer
|
|
SI1766010T1
(sl)
|
2004-06-28 |
2011-06-30 |
Univ Western Australia |
Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
|
|
WO2006088490A2
(en)
|
2004-06-30 |
2006-08-24 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
|
CN104558200B
(zh)
|
2004-09-02 |
2021-11-16 |
康石医药科技（上海）有限公司 |
改进的apo e类似物及其使用方法
|
|
WO2006031996A2
(en)
|
2004-09-14 |
2006-03-23 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeting viruses using a modified sindbis glycoprotein
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
US8357664B2
(en)
|
2004-10-26 |
2013-01-22 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
US7524829B2
(en)
|
2004-11-01 |
2009-04-28 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
JP2008532936A
(ja)
|
2005-02-14 |
2008-08-21 |
ワイス |
インターロイキン−１７ｆ抗体及び他のｉｌ−１７ｆシグナル伝達拮抗物質並びにそれらの使用
|
|
JP2008538500A
(ja)
|
2005-04-22 |
2008-10-30 |
アカデミス ツィーケンホイス ライデン |
ＳＲタンパク質の結合に対する干渉とＲＮＡ二次構造に対する干渉による、ｍＲＮＡ前駆体におけるエクソン認識の調節
|
|
WO2006114478A1
(en)
|
2005-04-26 |
2006-11-02 |
Karyon-Ctt Ltd |
Diagnostic and therapeutic agents
|
|
US7790694B2
(en)
|
2005-07-13 |
2010-09-07 |
Avi Biopharma Inc. |
Antisense antibacterial method and compound
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
EP1915161B1
(en)
|
2005-07-13 |
2017-04-26 |
Sarepta Therapeutics, Inc. |
Antisense antibacterial method and compound
|
|
US8524676B2
(en)
|
2005-09-08 |
2013-09-03 |
Sarepta Therapeutics, Inc. |
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
|
|
EP1937278B1
(en)
|
2005-09-08 |
2012-07-25 |
AVI BioPharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
EP1941275B1
(en)
|
2005-09-29 |
2013-07-24 |
Medimmune, Inc. |
Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
|
|
WO2007056466A2
(en)
|
2005-11-08 |
2007-05-18 |
Avi Biopharma, Inc. |
Immunosuppression compound and treatment method
|
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
|
AU2006315758A1
(en)
|
2005-11-10 |
2007-05-24 |
Ercole Biotech, Inc. |
Splice switching oligomers for TNF superfamily receptors and their use in treatment of disease
|
|
DE602007006457D1
(de)
|
2006-03-07 |
2010-06-24 |
Avi Biopharma Inc |
Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
|
|
US8785407B2
(en)
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
HUE036995T2
(hu)
|
2006-05-10 |
2018-08-28 |
Sarepta Therapeutics Inc |
Az alegységek között kationos kötéssel rendelkezõ oligonukleotid analógok
|
|
BRPI0621672A2
(pt)
|
2006-05-17 |
2012-07-10 |
Svetlana Anatolevna Sokolova |
veìculo
|
|
CA2558160C
(en)
|
2006-06-30 |
2017-01-03 |
Oligos Etc., Inc. |
Antisense oligonucleotide targeting myostatin or fox01 for treatment of muscle wasting
|
|
PT2049664E
(pt)
|
2006-08-11 |
2012-01-03 |
Prosensa Technologies Bv |
Oligonucleotídeos de cadeia simples complementares dos elementos repetitivos para tratar perturbações genéticas associadas à instabilidade das repetições do adn
|
|
US20080199961A1
(en)
|
2006-08-25 |
2008-08-21 |
Avi Biopharma, Inc. |
ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
|
|
US20080267978A1
(en)
|
2006-08-28 |
2008-10-30 |
Mary Zutter |
Anti-angiogenic targets for cancer therapy
|
|
EP2560001B1
(en)
|
2006-09-21 |
2016-04-13 |
University of Rochester |
Compositions and methods related to protein displacement therapy for myotonic distrophy
|
|
FR2908999B1
(fr)
|
2006-11-29 |
2012-04-27 |
Biomerieux Sa |
Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
|
|
EP1938802A1
(en)
|
2006-12-22 |
2008-07-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interfering RNAs targeting pro-inflammatory cytokines
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
AU2008271050B2
(en)
|
2007-06-29 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
WO2009008725A2
(en)
|
2007-07-12 |
2009-01-15 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
|
WO2009026412A1
(en)
|
2007-08-21 |
2009-02-26 |
Children's Medical Center Corporation |
Treatment of airway hyperreactivity
|
|
CA2704049A1
(en)
|
2007-10-26 |
2009-04-30 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
US8299206B2
(en)
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
MX2010004955A
(es)
|
2007-11-15 |
2010-06-30 |
Avi Biopharma Inc |
Metodo de sintesis de oligomeros de morfolina.
|
|
AU2008345033B2
(en)
|
2007-12-28 |
2014-04-03 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
WO2009144481A2
(en)
|
2008-05-30 |
2009-12-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CA3066050A1
(en)
|
2008-10-24 |
2010-04-29 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for dmd
|
|
PT2607484E
(pt)
|
2008-10-27 |
2016-03-09 |
Academisch Ziekenhuis Leiden |
Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
|
|
CA2744987C
(en)
|
2008-12-02 |
2018-01-16 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
US8592386B2
(en)
|
2008-12-17 |
2013-11-26 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
JP2012523225A
(ja)
|
2009-04-10 |
2012-10-04 |
アソシアシオン・アンスティテュ・ドゥ・ミオロジー |
疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
|
|
AU2010239779A1
(en)
|
2009-04-24 |
2011-11-17 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating DMD
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
BR112012000828A8
(pt)
|
2009-07-06 |
2017-10-10 |
Ontorii Inc |
Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
|
|
JP5878758B2
(ja)
|
2009-09-16 |
2016-03-08 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
Ｒｎａ及びその誘導体合成のための新規保護基
|
|
PL2499249T3
(pl)
|
2009-11-12 |
2019-03-29 |
Univ Western Australia |
Cząsteczki antysensowne i sposoby leczenia patologii
|
|
CA2805086C
(en)
|
2010-05-13 |
2020-10-20 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
|
WO2011150408A2
(en)
|
2010-05-28 |
2011-12-01 |
Avi Biopharma, Inc. |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
|
TWI541024B
(zh)
*
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
WO2012039448A1
(ja)
|
2010-09-24 |
2012-03-29 |
株式会社キラルジェン |
不斉補助基
|
|
US9078911B2
(en)
|
2011-02-08 |
2015-07-14 |
The Charlotte-Mecklenburg Hospital Authority |
Antisense oligonucleotides
|
|
EP2704749A1
(en)
*
|
2011-05-05 |
2014-03-12 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
US9161948B2
(en)
*
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
US9607308B2
(en)
|
2011-06-29 |
2017-03-28 |
American Express Travel Related Services Company, Inc. |
Spend based digital ad targeting and measurement
|
|
EP2581448B1
(en)
|
2011-10-13 |
2015-01-28 |
Association Institut de Myologie |
Tricyclo-phosphorothioate DNA
|
|
JP6496549B2
(ja)
|
2011-11-30 |
2019-04-03 |
サレプタ セラピューティクス， インコーポレイテッド |
脊髄性筋萎縮症における誘発されたエクソン包含
|
|
RU2619184C2
(ru)
|
2011-12-28 |
2017-05-12 |
Ниппон Синяку Ко., Лтд. |
Антисмысловые нуклеиновые кислоты
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
DE102012101676A1
(de)
|
2012-02-29 |
2013-08-29 |
Klaus-Dieter Rösler |
Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage
|
|
CA2877644A1
(en)
*
|
2012-07-03 |
2014-01-09 |
Prosensa Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
AU2013288048A1
(en)
|
2012-07-13 |
2015-01-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
|
KR20220139425A
(ko)
|
2012-07-13 |
2022-10-14 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
CA2894899A1
(en)
|
2012-12-20 |
2014-06-26 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
|
PT2970964T
(pt)
|
2013-03-14 |
2019-03-14 |
Sarepta Therapeutics Inc |
Composições de skipping de exões para o tratamento da distrofia muscular
|
|
EP3662912A1
(en)
*
|
2013-03-15 |
2020-06-10 |
Sarepta Therapeutics, Inc. |
Improved dosages of eteplirsen for treating duchenne muscular dystrophy
|
|
CN111235149B
(zh)
*
|
2013-09-05 |
2024-04-16 |
萨罗塔治疗公司(美国) |
酸性α-葡糖苷酶中反义诱导的外显子2纳入
|
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
PT3094728T
(pt)
|
2014-01-16 |
2022-05-19 |
Wave Life Sciences Ltd |
Desenho quiral
|
|
PL3118311T3
(pl)
|
2014-03-12 |
2019-09-30 |
Nippon Shinyaku Co., Ltd. |
Antysensowny kwas nukleinowy
|
|
CN106661577B
(zh)
|
2014-06-17 |
2020-05-12 |
日本新药株式会社 |
反义核酸
|
|
WO2016070166A2
(en)
|
2014-11-02 |
2016-05-06 |
Arcturus Therapeutics, Inc. |
Messenger una molecules and uses thereof
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
WO2017062835A2
(en)
*
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
EP3359523A4
(en)
|
2015-10-09 |
2019-07-24 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
|
MX2019006882A
(es)
*
|
2016-12-19 |
2019-08-16 |
Sarepta Therapeutics Inc |
Conjugados de oligomeros de omision de exon para distrofia muscular.
|
